In 2040, Canada will have an estimated 1.5 million people over 65 with heart valve disease (HVD). The incidence of HVD is markedly increasing with the aging of the population and should be considered one of the next epidemics affecting millions of people worldwide. Patients with HVD are often underdiagnosed, undertreated, and referred for care too late in the course of the disease. HVD can cause complications such as heart failure and stroke.
To address gaps in HVD care in Canada, the CCS formed a Heart Valve Disease Strategy Working Group with Dr. David Messika-Zeitoun as chair and Drs. Jessica Forcillo and David Wood as vice-chairs. The working group will provide a mechanism for stakeholders to help transforming the care for individuals living with HVD. The report will inform the goals and priorities for the Working Group.
Other NewsSee All
CCS national cardiac reporting system not funded in federal Budget 2021, but our efforts to advance heart health for all Canadians continue.
April 20, 2021
On behalf of the Canadian Cardiovascular Society (CCS), it is with regret that I share that our...Health policy